Workflow
Integrated Drug Creation™ platform
icon
Search documents
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
GlobeNewswire News Room· 2025-08-07 06:00
Core Insights - Almirall and Absci Corporation are expanding their AI Drug Discovery collaboration to include a second target for dermatological indications, building on the success of their initial collaboration [1][2][4] - The collaboration leverages Absci's Integrated Drug Creation™ platform and Almirall's dermatology expertise to accelerate the development of innovative therapeutics for chronic skin diseases [2][3] - Absci is eligible for up to approximately $650 million in payments across both programs, in addition to royalties on potential product sales [3] Company Overview - Almirall is a global biopharmaceutical company focused on medical dermatology, founded in 1944 and headquartered in Barcelona, with total revenue of €990 million in 2024 and over 2000 employees globally [5][6] - Absci is a clinical-stage biopharmaceutical company that utilizes generative AI for drug discovery, aiming to create better biologics faster [8][9] Collaboration Details - The initial collaboration, announced in November 2023, successfully delivered AI-designed functional antibody leads against a difficult-to-drug target [2][4] - Absci's generative AI platform is combined with wet lab capabilities to design and validate therapeutic candidates, while Almirall leads the preclinical and clinical development [3][4] - The collaboration aims to accelerate innovation in dermatology by utilizing generative AI for new therapeutic approaches [4]
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
Globenewswire· 2025-07-30 20:05
Company Overview - Absci Corporation is a clinical-stage biopharmaceutical company focused on advancing drug discovery through generative design, aiming to create better biologics for patients more rapidly [3] - The company utilizes its Integrated Drug Creation™ platform, which combines AI models with a synthetic biology data engine, to innovate therapeutics targeting challenging therapeutic areas [3] Upcoming Financial Results - Absci will report its business updates and financial results for the second quarter of 2025 after market close on August 12, 2025 [1] - A conference call will be held at 4:30 p.m. Eastern Time to discuss these results and the company's outlook, with a live webcast available on its investor relations website [2] Product Pipeline - Absci is developing a pipeline of AI-designed therapeutics, including ABS-101, aimed at treating inflammatory bowel disease (IBD), and ABS-201, which targets hair regrowth for androgenetic alopecia [3] - The company collaborates with leading pharmaceutical, biotech, tech, and academic institutions to enhance its therapeutic innovations [3]
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
Globenewswire· 2025-04-14 20:05
Company Overview - Absci Corporation is a data-first generative AI drug creation company focused on advancing drug discovery through generative design to create better biologics for patients more quickly [3] - The company utilizes its Integrated Drug Creation™ platform, which combines advanced AI models with a synthetic biology data engine, to rapidly design innovative therapeutics targeting challenging therapeutic areas [3] Upcoming Financial Reporting - Absci will report its business updates and financial results for the first quarter of 2025 after market close on May 13, 2025 [1] - A conference call will be held at 4:30 p.m. Eastern Time to discuss the business developments and financial results, with a live audio webcast available on the company's investor relations website [2] Product Pipeline - Absci is advancing its pipeline of AI-designed therapeutics, including ABS-101, aimed at treating inflammatory bowel disease (IBD), and ABS-201, which targets hair regrowth for androgenetic alopecia [3]
Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025
Globenewswire· 2025-03-04 21:05
Core Insights - Absci Corporation will report its business updates and financial results for Q4 and full year 2024 on March 18, 2025, after market close [1] - A conference call will be held at 4:30 p.m. Eastern Time to discuss the results and outlook, with a live webcast available on the company's investor relations website [2] Company Overview - Absci is a data-first generative AI drug creation company that integrates AI with scalable wet lab technologies to enhance the development of biologics [3] - The company's Integrated Drug Creation™ platform aims to accelerate the time to clinic and improve the probability of success by optimizing multiple drug characteristics simultaneously [3] - Absci can screen billions of cells weekly, transitioning from AI-designed candidates to wet lab-validated candidates in as little as six weeks [3]
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globenewswire· 2025-03-04 21:00
Core Points - Absci Corporation granted a non-statutory stock option to a newly-hired non-executive employee for 162,800 shares as part of its 2023 Inducement Plan [1][2] - The exercise price of the stock option is set at $3.42 per share, which is the closing price on the grant date [2] - The stock option has a 10-year term and vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting in approximately equal monthly installments over the next three years [2] Company Overview - Absci is a generative AI drug creation company that integrates AI with scalable wet lab technologies to enhance the development of biologics [3] - The company's Integrated Drug Creation™ platform aims to accelerate the time to clinic and improve the probability of success by optimizing multiple drug characteristics simultaneously [3] - Absci can screen billions of cells weekly, transitioning from AI-designed candidates to wet lab-validated candidates in as little as six weeks [3]
Absci to Participate in the KeyBanc Capital Markets Healthcare Forum
Globenewswire· 2025-03-04 13:00
Core Insights - Absci Corporation is a data-first generative AI drug creation company that will participate in the KeyBanc Capital Markets Healthcare Forum [1][2] - The company utilizes its Integrated Drug Creation™ platform to accelerate drug development and increase the probability of success by optimizing multiple drug characteristics [3] - Absci can screen billions of cells weekly, transitioning from AI-designed candidates to wet lab-validated candidates in as little as six weeks [3] Company Overview - Absci combines AI with scalable wet lab technologies to create biologics more efficiently for patients [3] - The company is headquartered in Vancouver, WA, with additional facilities in New York City and Zug, Switzerland [3] - Absci's investor relations website provides access to live and archived webcasts for interested parties [2]